<DOC>
	<DOCNO>NCT00004665</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate long-term safety tolerance synthetic formulation dehydroepiandrosterone , GL701 , patient systemic lupus erythematosus complete prior GL701 protocol .</brief_summary>
	<brief_title>Phase II Study Long-Term Dehydroepiandrosterone Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive daily oral dehydroepiandrosterone 12 month . The dose adjust base disease activity tolerance treatment . Patients follow every 3 month .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Systemic lupus erythematosus American College Rheumatology criterion Mild moderate disease characterize follow : Prednisone dose ( equivalent ) 10 30 mg/day No daily dose 1 mg/kg great No alternateday regimen Failed prednisone taper last 12 month dose stable least 6 week prior entry OR No attempt taper last 12 month dose stable least 3 month prior entry Prior completion dehydroepiandrosterone ( DHEA ) study require No prior participation doubleblind DHEA study Stanford University Prior/Concurrent Therapy No concurrent immunosuppressants No concurrent participation clinical study No investigational agent within long 30 day 10 halflives agent At least 3 month since immunosuppressant , include : Adrenocorticotropin hormone Androgens Cyclophosphamide Azathioprine Intravenous immune globulin At least 1 month since change dose nonsteroidal antiinflammatory drug hydroxychloroquine Patient Characteristics Age : 18 Sex : Female Performance status : Not specify Other : No hypersensitivity DHEA inactive ingredient GL701 formulation , i.e. , cornstarch , lactose , magnesium stearate No condition would prevent adequate compliance study No history breast cancer reproductive tract malignancy Negative pregnancy test require within 2 week prior entry Reliable contraception require fertile woman No estrogencontaining oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>